In this program project, we propose a Personalized Medicine approach to the study of advanced lung disease. We hypothesize that sub-phenotypes of common diseases, including pulmonary arterial hypertension (PAH), have a profound influence on outcome and responsiveness to therapy. The overarching translatlonal goal of this program is to define common mechanistic and therapeutic pathways for PAH in the context of major lung and systemic diseases, such as COPD and HIV. Our proposed three major projects and two cores are designed to integrate and synergize fundamental translatlonal research addressing major current and high impact problems in the PAH and advanced lung disease field. Because translational medicine requires a bench-to-bedside-to-bench integrated approach, we developed a full translatlonal continuum from preclinical models in three species, including a novel primate PAH model, screening and clinical drug development programs, human hemodynamic phenomic assessments, genetics, and clinical epidemiological trials focused initially on two major disease targets, COPD and HIV, which represent two prototypic models of the pulmonary hypertension sub-phenotype. Our three proposed projects and cores all individually and collaboratively align across this translational spectrum, driving an effort to understand fundamental mechanisms of disease, identify small molecule therapeutic agents, develop screening biomarkers for vascular sub-phenotypes of lung disease, and to set the stage for phase II and III clinical trials. Successes in the first five years of this project are expected to develop into phase ll-lll clinical trials and extension to other advanced lung diseases, such as interstitial lung disease and obstructive sleep apnea, in years 6 to 10. Project 1: Pulmonary hypertension in COPD: Genetic and Environmental Determinants Project 2: ROS signaling and NOS uncoupling in pulmonary vascular disease Project 3: Pulmonary vascular-targeted NO therapeutic strategies Core A: Administrative core Core B: Pre-Clinical Models of PAH Core C: Translational Vascular Phenomics, Genomics and Epidemiology Core

Public Health Relevance

Pulmonary vascular disease is a relatively understudied, but Important sub-phenotype in COPD, HIV, IPF, and OSA that is associated with excessive morbidity and mortality, and presents unique therapeutic opportunities.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL103455-02
Application #
8268999
Study Section
Special Emphasis Panel (ZHL1-CSR-A (M1))
Program Officer
Moore, Timothy M
Project Start
2011-06-01
Project End
2016-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
2
Fiscal Year
2012
Total Cost
$2,556,023
Indirect Cost
$868,879
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Woodcock, Chen-Shan Chen; Huang, Yi; Woodcock, Steven R et al. (2018) Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. J Biol Chem 293:1120-1137
Raghu, Vineet K; Ramsey, Joseph D; Morris, Alison et al. (2018) Comparison of strategies for scalable causal discovery of latent variable models from mixed data. Int J Data Sci Anal 6:33-45
Kudryashova, Tatiana V; Shen, Yuanjun; Pena, Andressa et al. (2018) Inhibitory Antibodies against Activin A and TGF-? Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Int J Mol Sci 19:
Freeman, Bruce A; O'Donnell, Valerie B; Schopfer, Francisco J (2018) The discovery of nitro-fatty acids as products of metabolic and inflammatory reactions and mediators of adaptive cell signaling. Nitric Oxide 77:106-111
Villacorta, Luis; Minarrieta, Lucia; Salvatore, Sonia R et al. (2018) In situ generation, metabolism and immunomodulatory signaling actions of nitro-conjugated linoleic acid in a murine model of inflammation. Redox Biol 15:522-531
Remy, Kenneth E; Cortés-Puch, Irene; Solomon, Steven B et al. (2018) Haptoglobin improves shock, lung injury, and survival in canine pneumonia. JCI Insight 3:
Rom, Oren; Khoo, Nicholas K H; Chen, Y Eugene et al. (2018) Inflammatory signaling and metabolic regulation by nitro-fatty acids. Nitric Oxide :
D'Amore, Antonio; Fazzari, Marco; Jiang, Hong-Bin et al. (2018) Nitro-Oleic Acid (NO2-OA) Release Enhances Regional Angiogenesis in a Rat Abdominal Wall Defect Model. Tissue Eng Part A 24:889-904
Schopfer, Francisco J; Vitturi, Dario A; Jorkasky, Diane K et al. (2018) Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases. Nitric Oxide 79:31-37
Farkas, Daniela; Thompson, A A Roger; Bhagwani, Aneel R et al. (2018) Toll-like Receptor 3 is a Therapeutic Target for Pulmonary Hypertension. Am J Respir Crit Care Med :

Showing the most recent 10 out of 182 publications